Monitoring changes in the microenvironment during targeted therapies

Published

Journal Article (Review)

Both antiangiogenic and vascular-targeted therapies hold great promise. The approval of some antiangiogenic agents in combination with other therapies bode well for the future clinical use of these agents. Similarly, the increased interest in vascular-targeting approaches shows potential, particularly when combined with radiotherapy and/or chemotherapy. In both of these approaches, however, it is imperative that suitable biomarkers be employed to monitor treatment effects and ensure optimal use. To achieve the highest efficacy of these treatment modalities, it may be mandatory to determine the response of antiangiogenic and antivascular compounds to ascertain an appropriate treatment schedule on an individualized basis (see Figure 1).

Duke Authors

Cited Authors

  • Wergin, M; Willett, CG; Dewhirst, MW

Published Date

  • October 1, 2007

Published In

Volume / Issue

  • 21 / 11

Start / End Page

  • 1354 - 1370

International Standard Serial Number (ISSN)

  • 0890-9091

Citation Source

  • Scopus